ALX Oncology

Rank#9200

Market Cap181.14M

CountryUnited States

Summary

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

History

ALX Oncology was founded in 2015 with a focus on researching and developing novel immunotherapies for the treatment of cancer. ALX Oncology has a portfolio of proprietary and partnered products consisting of monoclonal antibodies, bispecific antibodies, fusion proteins, and antibodies coupled with cytotoxic agents. The company has achieved a number of milestones including progressing several clinical studies, securing strategic partnerships, and growing its global presence.

Mission

To develop novel immunotherapies that target the tumour microenvironment and improve the lives of patients suffering from cancer.

Vision

To be a leader in immunotherapy of cancer and create a lasting impact on patients and the medical community.

References

https://in.investing.com/equities/alx-oncology-holdings

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/alexo-therapeutics-limited

https://finance.yahoo.com/quote/ALXO/

https://www.alxoncology.com

https://sec.report/CIK/0001810182

Leadership team